학술논문
An integrated prognostic model for diffuse large B‐cell lymphoma treated with immunochemotherapy
Document Type
Report
Author
Rodríguez, Marta; Alonso‐Alonso, Ruth; Fernández‐Miranda, Ismael; Mondéjar, Rufino; Cereceda, Laura; Tráscasa, Álvaro; Conceiçao, Anabel Antonio‐Da; Borregón, Jennifer; Gato, Lucía; Tomás‐Roca, Laura; Bárcena, Carmen; Iglesias, Begoña; Climent, Fina; González‐Barca, Eva; Camacho, Francisca Inmaculada; Mayordomo, Émpar; Olmedilla, Gabriel; Gómez‐Prieto, Pilar; Castro, Yolanda; Serrano‐López, Juana; Sánchez‐García, Joaquín; Montes‐Moreno, Santiago; García‐Cosío, Mónica; Martín‐Acosta, Paloma; García, Juan F.; Planelles, María; Quero, Cristina; Provencio, Mariano; Mahíllo‐Fernández, Ignacio; Rodríguez‐Pinilla, Socorro M.; Derenzini, Enrico; Pileri, Stefano; Sánchez‐Beato, Margarita; Córdoba, Raúl; Piris, Miguel A.
Source
ejHaem. August 2022, Vol. 3 Issue 3, p722, 12 p.
Subject
Language
English
Abstract
INTRODUCTION Diffuse large B‐cell lymphoma (DLBCL) is the most frequent non‐Hodgkin lymphoma subtype. It is a highly clinically, morphologically, and biologically heterogeneous group of aggressive lymphoproliferative disorders [1]. Although more [...]
: Diffuse large B‐cell lymphoma (DLBCL), the most frequent non‐Hodgkin's lymphoma subtype, is characterized by strong biological, morphological, and clinical heterogeneity, but patients are treated with immunochemotherapy in a relatively homogeneous way. Here, we have used a customized NanoString platform to analyze a series of 197 homogeneously treated DLBCL cases. The platform includes the most relevant genes or signatures known to be useful for predicting response to R‐CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) in DLBCL cases. We generated a risk score that combines the International Prognostic Index with cell of origin and double expression of MYC/BCL2, and stratified the series into three groups, yielding hazard ratios from 0.15 to 5.49 for overall survival, and from 0.17 to 5.04 for progression‐free survival. Group differences were highly significant (p < 0.0001), and the scoring system was applicable to younger patients (
: Diffuse large B‐cell lymphoma (DLBCL), the most frequent non‐Hodgkin's lymphoma subtype, is characterized by strong biological, morphological, and clinical heterogeneity, but patients are treated with immunochemotherapy in a relatively homogeneous way. Here, we have used a customized NanoString platform to analyze a series of 197 homogeneously treated DLBCL cases. The platform includes the most relevant genes or signatures known to be useful for predicting response to R‐CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) in DLBCL cases. We generated a risk score that combines the International Prognostic Index with cell of origin and double expression of MYC/BCL2, and stratified the series into three groups, yielding hazard ratios from 0.15 to 5.49 for overall survival, and from 0.17 to 5.04 for progression‐free survival. Group differences were highly significant (p < 0.0001), and the scoring system was applicable to younger patients (